These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 19146644)

  • 1. Successful treatment of refractory generalized myasthenia gravis with rituximab.
    Lebrun C; Bourg V; Tieulie N; Thomas P
    Eur J Neurol; 2009 Feb; 16(2):246-50. PubMed ID: 19146644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myasthenia gravis: emerging new therapy options.
    Sieb JP
    Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N; Patwa HS; Novella SP; Goldstein JM
    Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options in autoimmune myasthenia gravis.
    García-Carrasco M; Escárcega RO; Fuentes-Alexandro S; Riebeling C; Cervera R
    Autoimmun Rev; 2007 Jun; 6(6):373-8. PubMed ID: 17537383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Myasthenia gravis].
    Fleury MC; Tranchant C
    Rev Prat; 2008 Dec; 58(20):2217-24. PubMed ID: 19209651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.
    Gajra A; Vajpayee N; Grethlein SJ
    Am J Hematol; 2004 Oct; 77(2):196-7. PubMed ID: 15389902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myasthenia gravis.
    Silvestri NJ; Wolfe GI
    Semin Neurol; 2012 Jul; 32(3):215-26. PubMed ID: 23117946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.
    Nelson RP; Pascuzzi RM; Kessler K; Walsh LE; Faught PP; Ramanuja S; Pescovitz MD; Loehrer PJ
    J Clin Neuromuscul Dis; 2009 Jun; 10(4):170-7. PubMed ID: 19494727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenia gravis: new therapeutic approaches based on pathophysiology.
    Lewis RA
    J Neurol Sci; 2013 Oct; 333(1-2):93-8. PubMed ID: 23938353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.
    Hain B; Jordan K; Deschauer M; Zierz S
    Muscle Nerve; 2006 Apr; 33(4):575-80. PubMed ID: 16323216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis.
    Strober J; Cowan MJ; Horn BN
    Arch Neurol; 2009 May; 66(5):659-61. PubMed ID: 19433668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and monitoring of low dose rituximab in myasthenia gravis.
    Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-lasting treatment effect of rituximab in MuSK myasthenia.
    Díaz-Manera J; Martínez-Hernández E; Querol L; Klooster R; Rojas-García R; Suárez-Calvet X; Muñoz-Blanco JL; Mazia C; Straasheijm KR; Gallardo E; Juárez C; Verschuuren JJ; Illa I
    Neurology; 2012 Jan; 78(3):189-93. PubMed ID: 22218276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature.
    Koul R; Al Futaisi A; Abdwani R
    Pediatr Neurol; 2012 Sep; 47(3):209-12. PubMed ID: 22883288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment.
    Lau AY; Chan AY; Mok VC
    Hong Kong Med J; 2011 Feb; 17(1):77-9. PubMed ID: 21282832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-refractory myasthenia gravis.
    Silvestri NJ; Wolfe GI
    J Clin Neuromuscul Dis; 2014 Jun; 15(4):167-78. PubMed ID: 24872217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab for myasthenia gravis: three case reports and review of the literature.
    Stieglbauer K; Topakian R; Schäffer V; Aichner FT
    J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis.
    Shibata-Hamaguchi A; Samuraki M; Furui E; Iwasa K; Yoshikawa H; Hayashi S; Yamada M
    Acta Neurol Scand; 2007 Dec; 116(6):406-8. PubMed ID: 17986100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of myasthenia gravis.
    Schwendimann RN; Burton E; Minagar A
    Am J Ther; 2005; 12(3):262-8. PubMed ID: 15891271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.